Accelerate Diagnostics (AXDX) 10-K 1 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	Accelerate Diagnostics, Inc.
Entity Central Index Key	727,207
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 841.8
Entity Common Stock, Shares Outstanding		55,766,359
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 28,513	$ 19,244
Investments	80,648	58,519
Trade accounts receivable	1,946	34
Inventory	8,063	0
Prepaid expenses	850	468
Other current assets	468	183
Total current assets	120,488	78,448
Property and equipment, net	4,890	4,258
Intellectual property, net	134	146
Total assets	125,512	82,852
Current liabilities:
Accounts payable	2,080	992
Accrued liabilities	3,636	3,009
Deferred revenue and income	1,071	35
Total current liabilities	6,787	4,036
Long-term deferred income	0	1,000
Other long term liabilities	21	0
Total liabilities	6,808	5,036
Commitments and contingencies see Note 17, Commitments and Contingencies
Stockholders' equity:
Preferred shares, $0.001 par value	0	0
Common stock, $0.001 par value	56	52
Contributed capital	360,620	255,257
Accumulated deficit	(241,972)	(177,289)
Accumulated other comprehensive income (loss)	0	(204)
Total stockholders' equity	118,704	77,816
Total liabilities and stockholders' equity	$ 125,512	$ 82,852

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Preferred shares, par value (dollars per share)	$ 0.01	$ 0.01
Preferred shares, shares authorized	5,000,000	5,000,000
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0	0
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	55,673,810	51,516,309
Common stock, shares outstanding	55,673,810	51,516,309

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Net sales	$ 4,177	$ 246	$ 147
Cost of sales	1,002	0	0
Gross profit	3,175	246	147
Costs and expenses:
Research and development	22,301	29,564	27,142
Sales, general and administrative	45,058	37,183	18,554
Total costs and expenses	67,359	66,747	45,696
Loss from operations	(64,184)	(66,501)	(45,549)
Other income (expense):
Interest expense	0	0	(4)
Foreign currency exchange loss	(75)	(77)	(19)
Interest and dividend income	908	494	74
Interest expense	(184)	(23)	0
Total other income, net	649	394	51
Net loss before income taxes	(63,535)	(66,107)	(45,498)
Provision for income taxes	(493)	(267)	0
Net loss	$ (64,028)	$ (66,374)	$ (45,498)
Basic and diluted net loss per share (dollars per share)	$ (1.18)	$ (1.29)	$ (1.01)
Weighted average shares outstanding (shares)	54,073	51,276	44,998
Other comprehensive loss:
Net loss	$ (64,028)	$ (66,374)	$ (45,498)
Net unrealized loss on available-for-sale investments	(117)	(64)	(20)
Foreign currency translation adjustment	321	(128)	1
Comprehensive loss	$ (63,824)	$ (66,566)	$ (45,517)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Contributed Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning Balance, amount at Dec. 31, 2014	$ 65,991	$ 45	$ 131,356	$ (65,417)	$ 7
Beginning Balance (shares) at Dec. 31, 2014		44,640,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(45,498)			(45,498)
Issuance of common stock	103,351	$ 6	103,345
Issuance of common stock (shares)		6,426,000
Exercise of options and warrants	805		805
Exercise of options and warrants (shares)		125,000
Unrealized loss on available-for-sale securities	(20)				(20)
Foreign currency translation adjustment	1				1
Equity-based compensation	8,388		8,388
Ending Balance, amount at Dec. 31, 2015	133,018	$ 51	243,894	(110,915)	(12)
Ending Balance (shares) at Dec. 31, 2015		51,191,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(66,374)			(66,374)
Exercise of options and warrants	$ 1,497	$ 1	1,496
Exercise of options and warrants (shares)	158,743	314,000
Short swing profits (net of costs)	$ 866		866
Issuance of common stock under employee purchase plan	226		226
Issuance of common stock under employee purchase plan (shares)		11,000
Unrealized loss on available-for-sale securities	(64)				(64)
Foreign currency translation adjustment	(128)				(128)
Equity-based compensation	8,775		8,775
Ending Balance, amount at Dec. 31, 2016	77,816	$ 52	255,257	(177,289)	(204)
Ending Balance (shares) at Dec. 31, 2016		51,516,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative impact of accounting change for forfeitures	(655)			(655)
Net loss	(64,028)			(64,028)
Issuance of common stock	83,224	$ 3	83,221
Issuance of common stock (shares)		3,085,000
Exercise of options and warrants	$ 6,606	$ 1	6,605
Exercise of options and warrants (shares)	656,846	1,045,000
Issuance of common stock under employee purchase plan	$ 597		597
Issuance of common stock under employee purchase plan (shares)		28,000
Unrealized loss on available-for-sale securities	(117)				(117)
Foreign currency translation adjustment	321				321
Equity-based compensation	14,940		14,940
Ending Balance, amount at Dec. 31, 2017	$ 118,704	$ 56	$ 360,620	$ (241,972)	$ 0
Ending Balance (shares) at Dec. 31, 2017		55,674,000

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (64,028,000)	$ (66,374,000)	$ (45,498,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,184,000	2,340,000	1,782,000
Amortization of intangible assets	12,000	11,000	10,000
Amortization of investment discount	326,000	374,000	188,000
Equity-based compensation	13,933,000	8,775,000	8,388,000
Realized gain on available-for-sale securities	0	(6,000)	0
Loss on disposal of property and equipment	240,000	23,000	0
(Increase) decrease in assets:
Accounts receivable	(1,912,000)	43,000	1,000
Inventory	(7,759,000)	0	0
Prepaid expense and other	(174,000)	1,292,000	(1,241,000)
Other current assets	(285,000)	(171,000)	(12,000)
Increase (decrease) in liabilities:
Accounts payable	1,064,000	(1,242,000)	329,000
Accrued liabilities	596,000	1,619,000	827,000
Deferred revenue and income	36,000	(92,000)	100,000
Deferred compensation	21,000	0	0
Net cash used in operating activities	(55,746,000)	(53,408,000)	(35,126,000)
Cash flows from investing activities:
Purchases of equipment	(2,966,000)	(2,409,000)	(3,656,000)
Purchase of available-for-sale securities	(82,333,000)	(74,075,000)	(12,418,000)
Sales of available-for-sale securities	11,522,000	9,716,000	141,000
Maturity of available-for-sale securities	48,049,000	17,200,000	13,258,000
Net cash used in investing activities	(25,728,000)	(49,568,000)	(2,675,000)
Cash flows from financing activities:
Exercise of warrants and options	6,606,000	1,497,000	805,000
Common stock issuance cost	0	(814,000)	0
Issuance of common stock and warrants	83,821,000	226,000	104,165,000
Recovery of related party short-swing profits	0	866,000	0
Payments on capital lease obligations	0	(13,000)	(147,000)
Net cash provided by financing activities	90,427,000	1,762,000	104,823,000
Effect of exchange rate on cash	316,000	(127,000)	0
Increase (decrease) in cash and cash equivalents	9,269,000	(101,341,000)	67,022,000
Cash and cash equivalents, beginning of period	19,244,000	120,585,000	53,563,000
Cash and cash equivalents, end of period	$ 28,513,000	$ 19,244,000	$ 120,585,000

Organization and Nature of Busi

Organization and Nature of Business; Basis of Presentation; Principles of Consolidation	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation	NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or “the Company”) is an in vitro diagnostics company dedicated to providing solutions which improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), regarding annual financial reporting. All amounts are rounded to the nearest thousand dollars unless otherwise indicated. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances. Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation and had no effect on our net income, stockholders’ equity or cash flows. In the current period presentation and the revised prior period presentation, depreciation and amortization expenses are reported as a component of the individual costs and expenses as part of the statements of operations and comprehensive loss. The amount of depreciation and amortization expenses now reported as a component of research and development costs for the years ended December 31, 2017 , 2016 and 2015 , were $1.1 million , $1.4 million and $1.1 million , respectively. The amount of depreciation and amortization expenses now reported as a component of sales, general and administrative costs for the years ended December 31, 2017 , 2016 and 2015 , were $632,000 , $983,000 and $672,000 , respectively.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The Company’s consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The preparation of the Company’s consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventories, property and equipment, intangible assets, accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual result could differ materially from those estimates. Estimated Fair Value of Financial Instruments The Company follows ASC Topic 820, Fair Value Measurements and Disclosures which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories: • Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; • Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; • Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments. See Note 5, Fair Value of Financial Instruments for further information and related disclosures regarding the Company’s fair value measurements. Cash and Cash Equivalents All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal. Investments The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of debt securities in U.S. government and agency securities, corporate debt securities and certificates of deposit. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment’s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income (loss) . Inventory Inventory is stated at the lesser of cost or net realizable value, with cost determined on the first-in-first-out method. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense and spoilage are expensed as incurred and not included in overhead subject to capitalization. The Company maintains provisions for excess and obsolete inventory based on management’s estimates of forecasted demand and, where applicable, product expiration. The Company adopted Accounting Standards Update (“ASU”) 2015-11, Simplifying the Measurement of Inventory (Topic 310) Inventory on January 1, 2017. This ASU simplifies the subsequent measurement of inventory by using only the lower of cost or net realizable value. The adoption did not have an effect on the Company’s consolidated financial statements. Accounts Receivable Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable. Receivables are written off if reasonable collection efforts prove unsuccessful. The Company provides for allowances on a specific account basis. The Company has not included an allowance for doubtful accounts as of December 31, 2017 and 2016 , due to no circumstances arising that would indicate collection of any particular or grouping of customer accounts receivable is doubtful. Property and Equipment Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less. Property and equipment includes diagnostic instruments used for sales demonstrations and instruments under rental agreements. The Company retains title to the instruments under these arrangements. See Note 8, Property and Equipment for further information and related disclosures. Long-lived Assets Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset. Warranty Reserve Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the consolidated statements of operations and comprehensive loss. Product warranty reserve activity for the years ended December 31, 2017 and 2016 is as follows (in thousands): 2017 2016 Beginning balance $ 1 $ — Provisions 331 18 Warranty expenses incurred (140 ) (17 ) Ending balance $ 192 $ 1 We had no warranty reserve in 2015 as there were no commercial sales in 2015 that included warranty coverage. Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition , when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones. Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Revenue is recognized net of reserves, which includes rebates. We also provide instruments to customers under bundled rental agreements. Under these agreements, we install the instrument in the customer’s facility and provide service. The customer agrees to purchase consumable products at a stated price over the term of the agreement which is typically five years or less. Contracts sometimes have renewal clauses but such clauses do not provide for a bargain renewal option or penalize the customer if they do not renew. The instrument remains the Company’s property throughout the term of the agreement and there is no transfer of title upon expiration. Revenue is recognized as consumable products are shipped or delivered, depending on contract terms. For multiple element arrangements, the total consideration for an arrangement is allocated among the separate elements in the arrangement based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on: (1) vendor specific objective evidence (“VSOE”), if available; (2) third party evidence of selling price if VSOE is not available; or (3) an estimated selling price, if neither VSOE nor third party evidence is available. Estimated selling price is our best estimate of the selling price of an element in a transaction. The Company limits the amount of revenue recognized for delivered elements to the amount that is not contingent on the future delivery of products or services or other future performance obligations. Deferred revenue represents amounts received but not yet earned under existing agreements. Effective January 1, 2018, the Company will adopt changes to its revenue recognition policy. Refer to Recent Accounting Pronouncements for further details. Cost of Sales Cost of sales consists of raw materials, depreciation, direct labor and stock-based compensation expense, manufacturing overhead, facility costs and warranty costs. Shipping and Handling Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss. Leases The Company accounts for leases in accordance with ASC 840, Leases, which requires leases to be classified as either operating or capital leases. In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception. Other leases are classified as operating leases. Operating lease rent is recorded as an operating expense monthly. For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments. The asset is included with property and equipment on the balance sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the statements of operations and comprehensive loss. For the liability, the amount due within the next year is recorded as capital lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the balance sheet. Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the statements of operations and comprehensive loss. Equity-Based Compensation The Company awards stock options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method). The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. • Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award. • Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award. • Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term. • Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future. The Company records the fair value of Restricted Stock Units (“RSU's”) or Stock Grants (“SG's”) based on published closing market price on the day before the grant date. In January 2017, the Company implemented ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. Pursuant to this guidance, we made a policy election to account for forfeitures as they occur rather than on an estimated basis. For periods prior to the adoption of this ASU, the Company estimated the forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period. The rate was calculated separately for awards to the board of directors/executives and all other awards. Further information regarding this change is included in Note 15, Employee and Consultant Equity-Based Compensation . See Note 15, Employee and Consultant Equity-Based Compensation for further information. Income Taxes and Deferred Tax Assets Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment. The Company follows the provisions of ASC 740, Income Taxes , to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense. Foreign Currency Translation and Foreign Currency Transactions The Company follows ASC 830 Foreign Currency Matters , which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholder's equity. The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the consolidated statement of operations and comprehensive loss. Earnings Per Share The Company follows ASC 260, Earnings Per Share , which requires companies to present basic earnings per share and diluted earnings per share. Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive. Earnings per share are restated when certain transactions or events, including rights offerings determined to have bonus elements have occurred. See Note 14, Earnings Per Share for further information. Comprehensive Loss The Company follows ASC 220, Reporting Comprehensive Income , which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss). The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive income (loss). Recent Accounting Pronouncements In May 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-09, Compensation—Stock Compensation (Topic 718) Scope of Modification Accounting. This amendment clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. Historically, modifications to our share-based awards is rare. As such, we do not expect the application of this standard to have a significant impact on our consolidated financial statements. In March 2017, the FASB issued ASU 2017-08, Receivable-Nonrefundable Fees and Other Costs (Topic 310-20) Premium Amortization on Purchased Callable Debt Securities. This amendment shortens the amortization period for certain callable debt securities held at a premium. Specifically, the amendment requires premiums to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an “incurred loss” methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020, with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019, with early adoption permitted. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption. In January, 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall. This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets. The ASU is required for us on January 1, 2018. We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”). Topic 606 supersedes the revenue recognition requirements in ASU Topic 605, Revenue Recognition (“Topic 605”), and requires the recognition of revenue when promised goods or services are transferred to customers in an amount that reflects the considerations to which the entity expects to be entitled to in exchange for those goods or services. Topic 606 also includes Subtopic 340-40, Other Assets and Deferred Costs - Contracts with Customers , which discusses the deferral of incremental costs of obtaining a contract with a customer, including the period of amortization of such costs. Collectively, we refer to Topic 606 and Subtopic 340-40 as the “new standard”. The two permitted transition methods under the new standard are the full retrospective method, in which the new standard would be applied to each prior reporting period presented and the cumulative effect of applying the new standard would be recognized at the earliest period shown, or the modified retrospective method, in which the cumulative effect of applying the new standard would be recognized at the date of initial application. In the fourth quarter of 2017, we substantially completed our assessment of the new standard, including completing our historical contract reviews and our evaluation of incremental costs of obtaining a contract. We will adopt the new standard on January 1, 2018 under the modified retrospective method. We expect an immaterial transition adjustment and an immaterial impact to our net earnings on an ongoing basis.

Concentration of Credit Risk

Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Concentration of Credit Risk	NOTE 3. CONCENTRATION OF CREDIT RISK Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers. The Company’s main financial institution for banking operations held 82% and 57% of the Company’s cash and cash equivalents as of December 31, 2017 and December 31, 2016 , respectively. The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. At December 31, 2017 and 2016 , 24% and 29% , respectively, of the outstanding receivable balance was with one customer.

FDA Clearance

FDA Clearance	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
FDA Clearance	NOTE 4. FDA CLEARANCE On February 23, 2017, the U.S. Food and Drug Administration (“FDA”) granted Accelerate’s de novo request to market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. Due to various factors, the Company manufactured inventory in advance of regulatory approval (pre-launch inventory). On January 1, 2017, the regulatory review process had progressed to a point that objective and persuasive evidence of approval was sufficiently probable, and a future economic benefit existed. On January 1, 2017, the Company started capitalizing pre-launch inventory. Additional information regarding inventory is included in Item 8, Note 7, Inventory . Prior to January 1, 2017, all pre-launch inventory was expensed because a future economic benefit could not be asserted. Costs associated with the Company’s purchase of inventory were reported as research and development costs, or if the inventory was used in marketing evaluations, as sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 5. FAIR VALUE OF FINANCIAL INSTRUMENTS The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at December 31, 2017 and 2016 (see Note 2, Summary of Significant Accounting Policies for further information): December 31, 2017 (in thousands) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash and cash equivalents: Money market funds $ 7,832 $ — $ — $ 7,832 Investments: Certificates of deposit — 13,441 — 13,441 US Treasury securities 14,716 — — 14,716 US Agency securities — 8,459 — 8,459 Commercial paper — 9,171 — 9,171 Asset-backed securities — 3,025 — 3,025 Corporate notes and bonds — 31,836 — 31,836 Total investments 14,716 65,932 — 80,648 Total assets measured at fair value $ 22,548 $ 65,932 $ — $ 88,480 December 31, 2016 (in thousands) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash and cash equivalents: Money market funds $ 10,970 $ — $ — $ 10,970 Investments: Certificates of deposit — 7,257 — 7,257 US Treasury securities 8,544 — — 8,544 US Agency securities — 4,501 — 4,501 Asset-backed securities — 5,557 — 5,557 Corporate notes and bonds — 32,660 — 32,660 Total investments 8,544 49,975 — 58,519 Total assets measured at fair value $ 19,514 $ 49,975 $ — $ 69,489 Money market funds are included in cash and cash equivalents on the consolidated balance sheet. Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds and U.S. Treasury securities as these specific assets are liquid. Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs. There were no transfers between levels during the year ended December 31, 2017 .

Investments

Investments	12 Months Ended
	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Investments	NOTE 6. INVESTMENTS The following tables summarize the Company’s available-for-sale investments at December 31, 2017 and 2016 (in thousands): AVAILABLE-FOR-SALE INVESTMENTS December 31, 2017 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Certificates of deposit $ 13,441 $ — $ — $ 13,441 US Treasury securities 14,787 — (71 ) 14,716 US Agency securities 8,510 — (51 ) 8,459 Commercial paper 9,171 — — 9,171 Asset-backed securities 3,026 — (1 ) 3,025 Corporate notes and bonds 31,906 — (70 ) 31,836 Total $ 80,841 $ — $ (193 ) $ 80,648 AVAILABLE-FOR-SALE INVESTMENTS December 31, 2016 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Certificates of deposit $ 7,257 $ — $ — $ 7,257 US Treasury securities 8,553 1 (10 ) 8,544 US Agency securities 4,514 — (13 ) 4,501 Asset-backed securities 5,554 3 — 5,557 Corporate notes and bonds 32,717 3 (60 ) 32,660 Total $ 58,595 $ 7 $ (83 ) $ 58,519 The following table summarizes the maturities of the Company’s available-for-sale securities at December 31, 2017 , and 2016 (in thousands): AVAILABLE-FOR-SALE INVESTMENT MATURITIES (in thousands) At December 31, 2017 At December 31, 2016 Amortized Cost Fair Value Amortized Cost Fair Value Due in less than 1 year $ 55,801 $ 55,735 $ 45,391 $ 45,344 Due in 1-5 years 25,040 24,913 13,204 13,175 Total $ 80,841 $ 80,648 $ 58,595 $ 58,519 Proceeds from sales of marketable securities (including principal paydowns) for the years ended December 31, 2017 , and 2016 , were $11.5 million and $9.7 million , respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no realized gains from sales of marketable securities the year ended December 31, 2017 , and $6,000 gross realized gains from sales of marketable securities for year ended December 31, 2016 . The gross proceeds associated with the realized gains for the year ended December 31, 2016 were $7.2 million . No material balances were reclassified out of accumulated other comprehensive income (loss) for the years ended December 31, 2017 , 2016 and 2015 . No other-than-temporary impairments are recorded as no investments had a fair value that remained less than its cost for more than twelve months as of December 31, 2017 , and 2016 . The Company does not intend to sell investments and it is more likely than not that we will not be required to sell investments before recovering the amortized cost. Additional information regarding the fair value of our financial instruments is included in Item 8, Note 5, Fair Value of Financial Instruments .

Inventory

Inventory	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory	NOTE 7. INVENTORY Inventory is stated at the lesser of cost or net realizable value, with cost determined on the first-in-first-out method. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense and spoilage are expensed as incurred, and not included in overhead subject to capitalization. The Company maintains provisions for excess and obsolete inventory based on management’s estimates of forecasted demand and, where applicable, product expiration. Inventories consisted of the following at December 31, (in thousands): 2017 2016 Raw materials $ 4,220 $ — Work in process 377 — Finished goods 3,466 — Inventory, net $ 8,063 $ — See Note 4, FDA Clearance for further information related to 2016 inventory balances.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 8. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost and consisted of the following at December 31, (in thousands). PROPERTY AND EQUIPMENT (in thousands) 2017 2016 Computer equipment $ 2,756 $ 2,270 Technical equipment 3,348 2,427 Facilities 3,621 3,387 Instruments 1,400 — Capital projects in progress 349 1,010 Total property and equipment $ 11,474 $ 9,094 Accumulated depreciation - other (6,584 ) (4,836 ) Net property and equipment $ 4,890 $ 4,258 Depreciation expense (which includes amortization of capital lease assets) for the years ended December 31, 2017 , 2016 and 2015 , was $2.2 million , $2.3 million and $1.8 million , respectively.

License Agreements and Grants

License Agreements and Grants	12 Months Ended
	Dec. 31, 2017
Research and Development [Abstract]
License Agreements and Grants	NOTE 9. LICENSE AGREEMENTS AND GRANTS National Institute of Health Grant In February 2015, the National Institute of Health awarded Denver Health and the Company a five -year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test for carbepenem-resistant Enterobacteriaceae directly from whole blood. The cumulative award amount under these subawards is $885,000 . The amounts invoiced for the years ended December 31, 2017 , 2016 and 2015 was $240,000 , $74,000 and $483,000 , respectively. Arizona Commerce Authority In August 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of $1.0 million (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones: • Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below). • Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1). • Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2). • Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4.5 million . For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least $63,000 and offers health insurance benefits and pays at least 65% of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of December 31, 2017 , the Company has collected all of the $1.0 million in milestones. The full amount is recorded in deferred revenue and income until the economic development provisions of the grant have been satisfied in full, as there are “claw-back” provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the “claw-back” provisions expire in January 2018, we will recognize the grant as an offset to expense. Further details are included in Note 10, Deferred Revenue and Income . In January 2018, the “claw-back” provisions expired and the $1.0 million was recognized as an offset to expense. Arizona R&D Refundable Tax Credit Program The Company has applied for and met the program requirements to receive a “Certificate of Qualification” from the Arizona Commerce Authority (“Authority”) which allows the Company to be eligible for a partial refund of research and development investments (“Arizona R&D Refundable Tax Credit Program”). The amounts collected under this program are recorded as an offset to research and development expenses, and for the years ended December 31, 2017 , 2016 and 2015 , were $0 , $1.2 million and $647,000 , respectively. If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.

Deferred Revenue and Income

Deferred Revenue and Income	12 Months Ended
	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
Deferred Revenue and Income	NOTE 10. DEFERRED REVENUE AND INCOME Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following twelve months, the amount is reported as long-term deferred income. A summary of the balances as of December 31, follows (in thousands): 2017 2016 Products and services not yet delivered 71 35 Arizona Commerce Authority grant 1,000 — Total current deferred revenue and income $ 1,071 $ 35 Arizona Commerce Authority grant $ — $ 1,000 Total long-term deferred income $ — $ 1,000 Through December 31, 2017 , we received $1.0 million in milestone payments from the Arizona Commerce Authority under the Grant Agreement described in Note 9, License Agreements and Grants . As of December 31, 2017 , no such payments have been recognized in income, and we do not anticipate recognizing such payments as income until the “claw-back” provisions under the Grant Agreement expire in 2018. In January 2018, the “claw-back” provisions expired and the $1.0 million was recognized as an offset to expense. Deferred revenue of $114,000 was recognized and recorded as a component of net sales on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2016 . No material deferred revenue was recognized and recorded as a component of net sales during the year ended December 31, 2017 .

Stock Purchase

Stock Purchase	12 Months Ended
	Dec. 31, 2017
Securities Financing Transactions Disclosures [Abstract]
Stock Purchase	NOTE 11. STOCK PURCHASE In 2012, we entered into a Securities Purchase Agreement with Abeja Ventures, LLC (“Abeja”), pursuant to which the Company agreed to sell and issue to Abeja at a purchase price of $1.03 per share for an aggregate purchase price of $14.4 million ; (i) 14.0 million shares of the Company’s common stock (“Common Stock”); (ii) a warrant to purchase 7.0 million shares of Common Stock at an exercise price of $1.03 per share (the “ $1.03 Warrant”); and (iii) another warrant to purchase 7.0 million shares of Common Stock at an exercise price of $2.00 per share (the “ $2.00 Warrant”), with each warrant exercisable prior to the fifth anniversary of the closing of the transactions contemplated by the Securities Purchase Agreement (collectively, the “Investment”). The purchase of Common Stock and warrants pursuant to the Investment, which was consummated in June 2012, qualified for equity treatment under U.S. GAAP. The respective values of the warrants and Common Stock were calculated using their relative fair values and both are classified under Contributed Capital. The value therefore recorded for the warrants was $5.9 million and for the Common Stock was $8.5 million . Both warrants were exercisable until June 26, 2017, which was the fifth anniversary of the date on which the warrants were issued. In 2013, Abeja exercised in full its warrant to purchase 7.0 million shares of Common Stock at an exercise price of $1.03 per share. On the same date, Abeja also exercised the 92% of its warrant to purchase an additional 7.0 million shares of Common Stock at an exercise price of $2.00 per share (Abeja exercised such warrant for 6.4 million shares, leaving 571,160 shares unexercised on that date). The Company received aggregate funds of $20.1 million in connection with such exercises. Shares issued by the Company in connection with the warrant exercises were issued directly to the members of Abeja on a pro rata basis in accordance with their membership interests and written exercise instructions provided to the Company by Abeja. Immediately after giving effect to the warrant exercises, Abeja also distributed in kind to its members (on a pro rata basis in accordance with their membership interests) the remaining shares of Common Stock held by that entity. In 2016, warrants to purchase 155,289 shares were exercised at an exercise price of $2.00 leaving 415,871 warrants for shares unexercised at December 31, 2016 . The Company received funds totaling $311,000 in connection with these exercises which are recorded as common stock and contributed capital in the consolidated balance sheet. In 2017, warrants to purchase 370,307 shares were exercised at an exercise price of $2.00 leaving 45,564 warrants for shares unexercised. The Company received funds totaling $741,000 in connection with these exercises which are recorded as common stock and contributed capital in the Consolidated Balance Sheet. The remaining 45,564 warrants for shares expired on June 26, 2017 and went unexercised. At December 31, 2017 the Company did not carry any warrants for shares due to all warrants for shares being exercised or expired.

Public Offerings

Public Offerings	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Public Offerings	NOTE 12. PUBLIC OFFERINGS On December 9, 2015, the Company published a prospectus supplement underwritten by J.P. Morgan and Piper Jaffray (“2015 Underwriters”) offering 5.6 million shares of common stock with an option for the 2015 Underwriters to purchase up to 838,000 additional shares of common stock for a total of 6.4 million shares. The public offering price was $17.00 per share and underwriting discounts and commissions were $1.19 per share. Affiliates, including entities affiliated with one of Company's directors, Jack Schuler, and which together are our largest stockholders, purchased 2.9 million of the offered shares at the public offering price of $17.00 per share. This includes various types of sales or offers to sell. The 2015 Underwriters did not receive any underwriting discount or commissions on the sale of 2.4 million shares to such affiliates. The public offering was finalized and 6.4 million shares of common stock were delivered to the purchasers on or around December 15, 2015. Proceeds from the sale totaled $109.3 million less underwriting and other expenses of $5.9 million for net proceeds of $103.4 million . On May 9, 2017 , the Company published a prospectus supplement underwritten by J.P. Morgan Securities LLC, William Blair & Company, L.L.C., Piper Jaffray & Co. and BTIG, LLC (“2017 Underwriters”) offering 2.8 million shares of common stock with an option for the 2017 Underwriters to purchase up to 413,000 additional shares of common stock for a total of 3.2 million shares. The public offering price was $28.85 per share and underwriting discounts and commissions were $1.73 . The public offering was finalized and 2.8 million shares of common stock were delivered to the purchasers on or around May 15, 2017 . The 2017 Underwriters partially exercised their option to purchase an additional 335,000 shares, with the sale closing on June 14, 2017 , and the option as to the remaining shares expired June 15, 2017 . Proceeds from the sales totaled $89.0 million less underwriting discounts, commissions and other costs of $5.8 million for net proceeds of $83.2 million . The net proceeds will be used for general corporate purposes and to fund our commercialization efforts. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although we have no present commitments or agreements to do so. Accordingly, we will retain broad discretion over the use of these proceeds.

Related Party Transaction

Related Party Transaction	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transaction	NOTE 13. RELATED PARTY TRANSACTION In June 2016 , the Company recorded a net amount of $866,000 related to the recovery of short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended. The Company recognized these related party proceeds as an increase to contributed capital on the consolidated balance sheet.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 14. EARNINGS PER SHARE The financial statements show basic earnings (loss) per share. The Company’s net loss for the periods presented caused the inclusion of all outstanding warrants, restricted stocks and options to purchase our Common Stock to be antidilutive. As of December 31, 2017 , 2016 and 2015 , there were Common Stock options, restricted stocks and warrants exercisable for 7,352,281 , 7,313,245 and 6,778,580 shares of Common Stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.

Employee and Consultant Equity-

Employee and Consultant Equity-Based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee and Consultant Equity-Based Compensation	NOTE 15. EMPLOYEE AND CONSULTANT EQUITY-BASED COMPENSATION The Company has three equity based compensation plans, which are discussed below: Non-Qualified Stock Option Plan The Non-Qualified Stock Option Plan (the “Non-Qualified Plan”) was a stockholder-approved plan that provided for stock option grants to independent contractors, technical advisors and directors of the Company. The exercise price of each option, which has a maximum 10 year life, was established by the Company's Compensation Committee on the date of grant. As of December 31, 2017 , there were 280,000 options exercised under the Non-Qualified Plan and 0 that remain outstanding. The Non-Qualified Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so no further options are available for grant. 2004 Omnibus Stock Option Plan In December 2004, the Company’s stockholders approved the Omnibus Stock Option Plan and reserved 500,000 shares of its authorized but unissued Common Stock for stock options to be granted to employees, independent contractors, technical advisors and directors of the Company. The authorized shares in this plan were increased by 5,000,000 shares to an aggregate amount of 5,500,000 upon stockholder approval during the fiscal year ended July 31, 2012. As of December 31, 2017 , there were 658,994 options exercised under the 2004 Omnibus Stock Option Plan and 3,281,006 that remain outstanding. The 2004 Omnibus Stock Option Plan has been replaced by the 2012 Omnibus Equity Incentive Plan, so no further options are available for grant. 2012 Omnibus Equity Incentive Plan In December 2012, the Company’s stockholders approved the Company’s 2012 Omnibus Equity Incentive Plan to replace all prior plans (“Prior Plans”). The Prior Plans remain in effect until all awards granted under those plans have been exercised, forfeited, canceled, expired or otherwise terminated. In connection with the approval of such plan, all stock options, totaling 1,677,500 formerly available for new awards under the Prior Plans were transferred to the 2012 Omnibus Equity Incentive Plan. During the Company's Annual Meeting of Stockholders, stockholders approved amendments to the Company's 2012 Omnibus Equity Incentive Plan increasing the number of stock options of Common Stock reserved and available for grant by 4,000,000 in May 2014 and 2,000,000 in May 2017 resulting in a total of 7,677,500 reserved shares. Stock options granted under this plan typically vest either (i) one year after grant date, (ii) monthly over a one year period, (iii) annually over a five year period, or (iv) 40% two years after grant date and the remaining 60% monthly over the next three years. The maximum term is ten years. Restricted Stock Units (“RSU's”) granted under this plan typically vest either (i) annually over a five year period, or (ii) immediately. Stock Grants (“SG's”) granted under this plan vest immediately. As of December 31, 2017 , there were 621,216 options exercised as well as 18,011 RSU's and SG's released under the 2012 Omnibus Equity Incentive Plan. There were 4,071,275 shares remaining outstanding, leaving 2,966,998 available for grant. In December 2015, the Board of Directors voted to restrict new grants under the 2012 Omnibus Equity Incentive Plan to 200,000 shares until such time as the Company’s total available shares are increased. The Company's total available shares were increased in March 2016 terminating the restriction of new grants. Combined Stock Option Plans The following table summarizes option activity under all plans during the years ending December 31, 2017 , and December 31, 2016 and shows the exercisable shares as of December 31, 2017 : Stock Option Activity Number of Shares Weighted Average Exercise Price per Share Options Outstanding January 1, 2016 6,167,170 $ 6.91 Granted 1,024,050 14.05 Forfeited (147,663 ) 18.43 Exercised (158,743 ) 7.47 Expired (27,690 ) 4.87 Options Outstanding December 31, 2016 6,857,124 7.72 Granted 1,208,542 23.84 Forfeited (79,962 ) 17.82 Exercised (656,846 ) 8.93 Expired (727 ) 24.45 Options Outstanding December 31, 2017 7,328,131 10.16 Exercisable December 31, 2017 5,163,899 6.38 The cash received from the exercise of options during the year ending December 31, 2017 , was $5.9 million and the tax benefit realized was $0 for the same period. Upon exercise, shares are issued from shares authorized and held in reserve. The intrinsic value of options exercised was $12.1 million , $2.2 million and $2.0 million for the years ending December 31, 2017 , 2016 and 2015 , respectively. The total fair value of options vesting during the period was $12.0 million , $6.6 million , and $7.3 million for the years ending December 31, 2017 , 2016 and 2015 , respectively. The Company accounts for all option grants using the Black-Scholes option pricing model in accordance with ASC 718 for options granted or extended. The table below summarizes the inputs used to calculate the estimated fair value of options awarded during the respective periods: Black-Scholes Assumptions for Options Granted Years ended December 31, 2017 2016 2015 Expected term (in years) 6.23 6.43 6.26 Volatility 77 % 86 % 91 % Expected dividends — — — Risk free interest rates 2.1 % 1.6 % 1.7 % Estimated forfeitures — % 8.5 % 5.6 % Weighted average fair value $ 16.24 $ 10.35 $ 16.69 In general, option awards have a requisite service period and unvested options are forfeited upon employee or consultant termination. In years prior to 2016, the Company estimated a forfeiture rate which was applied to outstanding options to determine options expected to be forfeited with the remaining outstanding options being those expected to vest. Effective January 2017, the Company implemented ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting and made a policy election to account for forfeitures as they occur. Further information regarding this implementation is included below in this note. The following table shows summary information for outstanding options and options that are exercisable (vested) as of December 31, 2017 : Stock Option Supplemental Information Options Outstanding Options Exercisable Number of options 7,328,131 5,163,899 Weighted average remaining contractual term (in years) 6.16 5.19 Weighted average exercise price $ 10.16 $ 6.38 Weighted average fair value $ 7.48 $ 4.74 Aggregate intrinsic value (in millions) $ 117.7 $ 102.4 The aggregate intrinsic value in the table above represents the total pretax intrinsic value that would have been received by the option holders had all option holders exercised their options on that date. It is calculated as the difference between the Company’s closing stock price of $26.20 on the last trading day of 2017 and the exercise price multiplied by the number of shares for options where the exercise price is below the closing stock price. This amount changes based on the fair market value of the Company’s stock. In December 2015, in connection with the Company's public offering, we modified the stock options of three of our executive officers to restrict the ability to exercise until such time as additional available unissued shares have been authorized. Such authorization was obtained from a majority of our shareholders as of December 31, 2015, and was filed with the State of Delaware in March 2016. There was an immaterial amount of incremental compensation associated with this modification. The following table summarizes RSU and SG activity during the years ending December 31, 2017 , and December 31, 2016 : RSU and SG Activity Number of Shares Weighted Average Grant Date Fair Value per Share RSU's & SG Outstanding January 1, 2016 40,250 20.91 Granted — — Forfeited — — Vested/released — — RSU's & SG's outstanding December 31, 2016 40,250 20.91 Granted 1,911 22.40 Forfeited — — Vested/released (18,011 ) 21.07 RSU's & SG's outstanding December 31, 2017 24,150 20.91 The total fair value of RSU's and SG's vested and released during the period was $379,000 , $0 , and $0 for the years ending December 31, 2017 , 2016 and 2015 , respectively. The Company records compensation cost based on the fair value of the award. The table below summarizes the weighted average fair value of RSU's and SG's awarded for the years ending December 31, : RSU and SG Grants 2017 2016 2015 Weighted average fair value 22.40 — 20.91 The expense and tax benefits recognized on the Company’s consolidated statements of operations and comprehensive loss related to options for the years ending December 31, is summarized below (in thousands): Equity-Based Compensation Expenses and Tax Benefit (in thousands) 2017 2016 2015 Cost of Sales $ 99 $ — $ — Research and development $ 3,738 $ 1,585 $ 2,479 Sales, general and administrative 10,096 7,190 5,909 Total equity-based compensation expense 13,933 8,775 8,388 Recognized tax benefit $ — $ — $ — As of December 31, 2017 , $304,000 and $48,000 of equity-based compensation expense was a component of capitalized inventory and property and equipment, respectively. As of December 31, 2017 , unrecognized equity-based compensation cost related to unvested stock options, and unvested RSU's was $15.9 million and $ 174,000 , respectively. This is expected to be recognized over the years 2018 through 2022 . In January 2017, we implemented ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. Pursuant to this guidance, we made a policy election to account for forfeitures as they occur rather than on an estimated basis and, therefore, equity based compensation expense for the year ended December 31, 2017 has been calculated based on actual forfeitures in our condensed consolidated statements of operations and comprehensive loss, rather than our previous approach which was net of estimated forfeitures. Share-based compensation expense for the years ending December 31, 2016 and December 31, 2015 is recorded net of estimated forfeitures, which were based on historical forfeitures and adjusted to reflect changes in facts and circumstances, if any. This change was accounted for using the modified retrospective transition method. This election resulted in a cumulative-effect adjustment which increased our accumulated deficit and additional paid-in capital by $655,000 for all outstanding awards as of January 1, 2017. We believe this election simplifies several aspects of the accounting for share-based payment transactions. This new guidance requires that we record excess tax benefits and tax deficiencies related to the settlement of employee stock-based compensation to the income tax expense line item on our condensed consolidated statements of operations and comprehensive loss. The new guidance also states that previously unrecognized excess tax benefits should be recognized on a modified retrospective basis as of the beginning of the annual period of adoption. At January 1, 2017, we recorded approximately $1.5 million of additional deferred tax assets, which are fully offset by a valuation allowance. Accordingly, the adoption of ASU 2016-09 did not result in an adjustment to retained earnings for the cumulative effect of the tax benefit of the stock compensation. The new guidance also requires excess tax benefits to be classified as an operating activity in the statement of cash flows rather than as a financing activity. Additionally, ASU 2016-09 requires that the minimum tax withholding paid on behalf of employees for share-based awards be classified as a financing activity in the statement of cash flows. Adoption of ASU 2016-09 did not result in any adjustments to prior period disclosures on the Company's consolidated statement of cash flows.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 16. INCOME TAXES The components of the pretax loss from operations for the years ended December 31, are as follows (in thousands): 2017 2016 2015 U.S. Domestic $ (46,849 ) $ (48,539 ) $ (44,415 ) Foreign (16,686 ) (17,568 ) (1,083 ) Pretax loss from operations $ (63,535 ) $ (66,107 ) $ (45,498 ) The components of the provision for income taxes for the years ended December 31, is presented in the following table: 2017 2016 2015 Current: Federal $ — $ — $ — State — — — Foreign 493 267 — Total current provision 493 267 — Deferred: Federal — — — State — — — Foreign — — — Total deferred provision — — — Total provision $ 493 $ 267 $ — On December 22, 2017, President Trump signed into law the Tax Cuts and Jobs Act (the Tax Act”). The Tax Act reduced the corporate tax rate from the maximum federal statutory rate of 35% to 21%. The Tax Act states that the 21% corporate tax rate is effective for tax years beginning on or after January 1, 2018. However, existing tax law, which was not amended under the Tax Act, governs when a change in tax rate is effective. Existing tax law provides that if the taxable year includes the effective date of any rate change (unless the change is the first date of the taxable year), taxes should be calculated by applying a blended rate to the taxable income for the year. For the Company, the net deferred tax assets for US purposes have been revalued to 21% as of December 31, 2017 with a corresponding adjustment to the valuation allowance. Therefore, the reduction in the US corporate tax rate had no impact to the Company's earnings. Due to uncertainties which currently exist in the interpretation of the provisions of the Tax Cuts and Jobs Act of 2017 regarding Internal Revenue Code Section 162(m), the Company has not evaluated the potential impacts of IRC Section 162(m) as amended by the Tax Cuts and Jobs Act of 2017 on its financial statements. In conjunction with the Tax Act, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has recognized the provisional tax impacts related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2017 . The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred income taxes for the years ended December 31, are as follows (in thousands): 2017 2016 Deferred tax assets: Net operating loss carryforward $ 41,086 $ 42,013 Property & equipment 524 690 Inventory 58 1,735 Stock options 8,195 7,208 Intangible assets, definite-lived 42 220 General business credit 6,651 3,984 Deferred revenue 253 370 Other 45 121 Valuation allowance (56,854 ) (56,341 ) Deferred tax assets $ — $ — As of December 31, 2017 , the Company generated regular tax federal net operating losses of approximately $173.4 million . The Company's ability to realize tax benefit from the net operating loss is subject to annual limitation under Internal Revenue Code Section 382. The Company will never get the benefit of $4.2 million of the net operating losses generated prior to June 26, 2012. The deferred tax asset has been adjusted to reflect the Section 382 limitation. The net operating losses available for future use are approximately $169.2 million . As a result of The Act, for U.S. income tax purposes, net operating losses can be carried forward for up to 20 years. The Company’s federal net operating losses will begin to expire in 2023. As of December 31, 2017 , the Company has generated Arizona net operating losses of approximately $142.8 million . The Company's Arizona net operating losses will begin to expire in 2033. The net deferred tax asset valuation allowance is $56.9 million as of December 31, 2017 , compared to $56.3 million as of December 31, 2016 . The valuation allowance is based on management’s assessment that it is more likely than not that the Company will not have taxable income in the foreseeable future. Due to the Company's consolidated loss position, the Company maintains a valuation allowance against its deferred tax assets. The Company began commercialization of its products in Europe in 2016 and has subsidiaries in the Netherlands, France, Germany, Italy, Spain and the United Kingdom. The Company intends to treat earnings from its foreign subsidiaries as permanently reinvested. The difference between the U.S. federal statutory income tax rate and the Company’s effective tax rate for years ending December 31, is as follows: 2017 2016 2015 U.S. federal statutory income tax rate (34.00 )% (34.00 )% (34.00 )% State taxes, net of federal tax benefit (2.62 ) (1.69 ) (2.93 ) Permanent and other differences (2.31 ) (0.17 ) 0.11 Change in tax rates (1.02 ) 0.67 — Tax rate differential 8.99 8.62 0.42 Tax cuts and jobs act 38.46 — — Unrecognized tax benefits 1.20 1.09 0.40 Nondeductible equity and other compensation (4.31 ) 1.17 2.86 Limitation on net operating losses due to §382 — — — Credit for increased research activities (4.42 ) (3.31 ) (2.67 ) Change in Valuation allowance 0.81 28.02 35.81 0.78 % 0.40 % — % The Company's uncertain tax positions at December 31, as follows (in thousands): 2017 2016 2015 Balance at beginning of year $ 1,101 $ 343 $ 161 Increases for prior positions 97 37 — Increases for current year positions 943 721 182 Other increases — — — Decreases due to settlements — — — Expiration of the statute of limitations for the assessment of taxes — — — Other decreases — — — Balance at end of year $ 2,141 $ 1,101 $ 343 These uncertain positions are not expected to change within the next twelve months. Of the $2.1 million of uncertain tax positions, $65,000 would impact the effective tax rate, if reversed. The Company accounts for interest on uncertain tax positions within tax expense. The Company's foreign subsidiaries are subject to applicable jurisdiction examination for all years of operations. The Company did not accrue interest or penalties for these uncertain tax positions as of December 31, 2017 . The Company has incurred federal net operating losses dating to the tax year ended July 31, 2004. As such, all loss carryovers are subject to adjustment under IRS and state examination, depending on the jurisdiction in which they were incurred. In 2016, the IRS began an examination of the Company’s 2014 income tax return. The Company completed the IRS audit of the 2014 income tax return with no change.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 17. COMMITMENTS AND CONTINGENCIES General Estimated losses from contingencies are accrued by a charge to income when information available prior to issuance of the financial statements indicates that it is probable that a liability could be incurred and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the contingency and estimated range of loss, if determinable, is made in the financial statements when it is at least reasonably possible that a material loss could be incurred. Leases The Company has entered into lease agreements, lease amendments, and lease extensions (“Lease Agreements”) for office, laboratory and manufacturing space located in Tucson, Arizona and Europe, the last of which expires in 2018. Total rent expense including common area charges was $1.3 million , $1.1 million and $685,000 for the years ended December 31, 2017 , 2016 and 2015 , respectively. Future minimum lease payments under these agreements are as follows (in thousands): 2018 $ 1,119 2019 200 2020 84 2021 47 Thereafter 4 Total $ 1,454 Clinical Trial Agreements The Company has entered into master agreements with clinical trial sites in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation. Clinical trial master agreement expense was $27,000 , $2.1 million and $1.6 million and for years ended December 31, 2017 , 2016 and 2015 , respectively. The expense incurred as part of the clinical trial is included in research and development on the Company's consolidated statements of operations and comprehensive loss. Marketing Study and Contracted Research The Company has entered into marketing study agreements and contracted research agreements with research institutions and hospitals in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation.

Industry and Geographic Informa

Industry and Geographic Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Industry and Geographic Information	NOTE 18. INDUSTRY AND GEOGRAPHIC INFORMATION The Company operates as one operating segment. Sales to customers outside the U.S. represented 28% , 3% and 0% of total revenue for the years ended December 31, 2017 , 2016 and 2015 , respectively. As of December 31, 2017 , 2016 , balances due from foreign customers, in U.S. dollars, were $1.0 million and $3,000 , respectively. For the year ended December 31, 2017 the Company had sales to one customer in excess of 10%; this customers balance represented 18% of total net sales. The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long lived assets as of Total revenue December31, for the years ended December 31, 2017 2016 2017 2016 2015 Domestic $ 3,779 $ 4,150 $ 3,016 $ 238 $ 147 Foreign 1,111 108 1,161 8 — $ 4,890 $ 4,258 $ 4,177 $ 246 $ 147

Supplemental Data (Unaudited)

Supplemental Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Supplemental Data (Unaudited)	The following is a summary of unaudited selected quarterly financial information for the three months ended (in thousands, except per share data): December 31, September 30, June 30, March 31, 2017 2017 2017 2017 Revenue $ 2,120 $ 828 $ 699 $ 530 Gross profit $ 1,470 $ 637 $ 564 $ 504 Loss from operations $ (16,136 ) $ (17,315 ) $ (16,423 ) $ (14,310 ) Net loss $ (16,296 ) $ (17,075 ) $ (16,457 ) $ (14,200 ) Basic and diluted net loss per share $ (0.29 ) $ (0.31 ) $ (0.31 ) $ (0.27 ) December 31, September 30, June 30, March 31, 2016 2016 2016 2016 Revenue $ 39 $ 24 $ 20 $ 163 Gross profit $ 39 $ 24 $ 20 $ 163 Loss from operations $ (16,024 ) $ (17,416 ) $ (17,889 ) $ (15,172 ) Net loss $ (16,135 ) $ (17,299 ) $ (17,866 ) $ (15,074 ) Basic and diluted net loss per share $ (0.31 ) $ (0.34 ) $ (0.35 ) $ (0.29 )

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), regarding annual financial reporting. All amounts are rounded to the nearest thousand dollars unless otherwise indicated.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.
Reclassification	Reclassification Certain prior year amounts have been reclassified for consistency with the current year presentation and had no effect on our net income, stockholders’ equity or cash flows. In the current period presentation and the revised prior period presentation, depreciation and amortization expenses are reported as a component of the individual costs and expenses as part of the statements of operations and comprehensive loss.
Use of Estimates	Use of Estimates
Estimated Fair Value of Financial Instruments	Estimated Fair Value of Financial Instruments The Company follows ASC Topic 820, Fair Value Measurements and Disclosures which has defined fair value and requires the Company to establish a framework for measuring fair value and disclose fair value measurements. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories: • Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; • Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability; • Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.
Investments	Investments The Company invests excess funds in various investments which are primarily held in the custody of major financial institutions. Investments consist of debt securities in U.S. government and agency securities, corporate debt securities and certificates of deposit. Management classifies its investments as available-for-sale investments and records these investments in the condensed consolidated balance sheet at fair value. The Company considers all available-for-sale securities, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations. The Company assesses whether an other-than-temporary impairment loss has occurred due to declines in fair value or other market conditions when an investment’s fair value remains less than its cost for more than twelve months. This assessment includes a determination of whether the investment is expected to recover in value and whether the Company has the intent and ability to hold the investment until the anticipated recovery in value occurs. When an investment is identified as having an other-than-temporary impairment loss, we adjust the cost basis of the investment down to fair value resulting in a realized loss. The new cost basis is not changed for subsequent recoveries in fair value and temporary future increases or decreases in fair value are included in other comprehensive income (loss) .
Inventory	Inventory Inventory is stated at the lesser of cost or net realizable value, with cost determined on the first-in-first-out method. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense and spoilage are expensed as incurred and not included in overhead subject to capitalization. The Company maintains provisions for excess and obsolete inventory based on management’s estimates of forecasted demand and, where applicable, product expiration. The Company adopted Accounting Standards Update (“ASU”) 2015-11, Simplifying the Measurement of Inventory (Topic 310) Inventory on January 1, 2017. This ASU simplifies the subsequent measurement of inventory by using only the lower of cost or net realizable value. The adoption did not have an effect on the Company’s consolidated financial statements.
Accounts Receivable Allowances	Accounts Receivable Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable. Receivables are written off if reasonable collection efforts prove unsuccessful. The Company provides for allowances on a specific account basis. The Company has not included an allowance for doubtful accounts as of December 31, 2017 and 2016 , due to no circumstances arising that would indicate collection of any particular or grouping of customer accounts receivable is doubtful.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less. Property and equipment includes diagnostic instruments used for sales demonstrations and instruments under rental agreements. The Company retains title to the instruments under these arrangements.
Long-lived Assets	Long-lived Assets Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.
Warranty Reserve	Warranty Reserve Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the consolidated statements of operations and comprehensive loss.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition , when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered. Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones. Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Revenue is recognized net of reserves, which includes rebates. We also provide instruments to customers under bundled rental agreements. Under these agreements, we install the instrument in the customer’s facility and provide service. The customer agrees to purchase consumable products at a stated price over the term of the agreement which is typically five years or less. Contracts sometimes have renewal clauses but such clauses do not provide for a bargain renewal option or penalize the customer if they do not renew. The instrument remains the Company’s property throughout the term of the agreement and there is no transfer of title upon expiration. Revenue is recognized as consumable products are shipped or delivered, depending on contract terms. For multiple element arrangements, the total consideration for an arrangement is allocated among the separate elements in the arrangement based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on: (1) vendor specific objective evidence (“VSOE”), if available; (2) third party evidence of selling price if VSOE is not available; or (3) an estimated selling price, if neither VSOE nor third party evidence is available. Estimated selling price is our best estimate of the selling price of an element in a transaction. The Company limits the amount of revenue recognized for delivered elements to the amount that is not contingent on the future delivery of products or services or other future performance obligations. Deferred revenue represents amounts received but not yet earned under existing agreements. Effective January 1, 2018, the Company will adopt changes to its revenue recognition policy. Refer to Recent Accounting Pronouncements for further details.
Cost of Sales	Cost of Sales Cost of sales consists of raw materials, depreciation, direct labor and stock-based compensation expense, manufacturing overhead, facility costs and warranty costs.
Shipping and Handling	Shipping and Handling Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.
Leases	Leases The Company accounts for leases in accordance with ASC 840, Leases, which requires leases to be classified as either operating or capital leases. In general, the Company classifies leases as capital leases when there is either a transfer of ownership at the end of the lease term, the lease contains a bargain purchase option, the lease term is seventy-five percent or more of the estimated economic life of the leased property or the minimum lease payments are ninety percent or more of the fair value at lease inception. Other leases are classified as operating leases. Operating lease rent is recorded as an operating expense monthly. For capital leases, both an asset and liability are recorded at the inception of the lease based on the present value of lease payments. The asset is included with property and equipment on the balance sheet and amortization is recorded on a straight-line basis over the term of the lease with the amortization expense included with depreciation on the statements of operations and comprehensive loss. For the liability, the amount due within the next year is recorded as capital lease obligations and the amount due in more than a year is recorded as long-term capital lease obligation on the balance sheet. Interest expense is recorded based on the implicit or explicit interest rate used in the lease and is included as non-operating interest expense on the statements of operations and comprehensive loss.
Equity-Based Compensation	Equity-Based Compensation The Company awards stock options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method). The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. • Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award. • Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award. • Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term. • Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future. The Company records the fair value of Restricted Stock Units (“RSU's”) or Stock Grants (“SG's”) based on published closing market price on the day before the grant date. In January 2017, the Company implemented ASU 2016-09, Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. Pursuant to this guidance, we made a policy election to account for forfeitures as they occur rather than on an estimated basis. For periods prior to the adoption of this ASU, the Company estimated the forfeiture rate of unvested awards based on the forfeitures in the previous twelve-month period. The rate was calculated separately for awards to the board of directors/executives and all other awards. Further information regarding this change is included in Note 15, Employee and Consultant Equity-Based Compensation .
Income Taxes and Deferred Tax Assets	Income Taxes and Deferred Tax Assets Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment. The Company follows the provisions of ASC 740, Income Taxes , to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The Company follows ASC 830 Foreign Currency Matters , which provides guidance on foreign currency transactions and translation of financial statements. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of stockholder's equity. The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the consolidated statement of operations and comprehensive loss.
Earnings Per Share	Earnings Per Share The Company follows ASC 260, Earnings Per Share , which requires companies to present basic earnings per share and diluted earnings per share. Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share are computed similarly to basic earnings (loss) per share except the denominator includes additional common shares that would have been outstanding if warrants and share-based payments had been issued. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive. Earnings per share are restated when certain transactions or events, including rights offerings determined to have bonus elements have occurred.
Comprehensive Loss	Comprehensive Loss The Company follows ASC 220, Reporting Comprehensive Income , which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss). The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive income (loss).
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-09, Compensation—Stock Compensation (Topic 718) Scope of Modification Accounting. This amendment clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. Early adoption is permitted. Historically, modifications to our share-based awards is rare. As such, we do not expect the application of this standard to have a significant impact on our consolidated financial statements. In March 2017, the FASB issued ASU 2017-08, Receivable-Nonrefundable Fees and Other Costs (Topic 310-20) Premium Amortization on Purchased Callable Debt Securities. This amendment shortens the amortization period for certain callable debt securities held at a premium. Specifically, the amendment requires premiums to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments-Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, which amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Currently, an “incurred loss” methodology is used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. The amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities will be recorded in the current period net income. The amendment will be effective for us on January 1, 2020, with early adoption permitted. We do not anticipate this guidance will have a significant impact on our financial statements and plan to adopt on the effective date. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This replaces the existing standards relating to leases for both lessees and lessors. For lessees, the new standard requires most leases to be recorded on the balance sheet with expenses recognized much like the existing standard. For lessors, the new standard modifies the classification criteria and accounting for sales-type and direct financing leases and eliminates leveraged leases. For both lessees and lessors, the standard eliminates real estate-specific provisions, changes some of the presentation and disclosure requirements, and changes sale and leaseback criteria. The ASU is required for us on January 1, 2019, with early adoption permitted. We are currently assessing the impact this will have on our consolidated financial statements and the timing of adoption. In January, 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall. This standard requires equity investments, with some exceptions, be measured at fair value with valuation changes recognized in net income, simplifies the impairment assessment of some equity investments, eliminates the requirement to disclose the methods and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost, requires the use of the exit price notion when measuring the fair value of financial instruments, requires separate presentation of some changes in other comprehensive income, requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets, and clarifies the need for a valuation allowance on some deferred tax assets. The ASU is required for us on January 1, 2018. We do not expect the adoption of ASU 2016-01 to have a significant impact on our consolidated financial statements. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“Topic 606”). Topic 606 supersedes the revenue recognition requirements in ASU Topic 605, Revenue Recognition (“Topic 605”), and requires the recognition of revenue when promised goods or services are transferred to customers in an amount that reflects the considerations to which the entity expects to be entitled to in exchange for those goods or services. Topic 606 also includes Subtopic 340-40, Other Assets and Deferred Costs - Contracts with Customers , which discusses the deferral of incremental costs of obtaining a contract with a customer, including the period of amortization of such costs. Collectively, we refer to Topic 606 and Subtopic 340-40 as the “new standard”. The two permitted transition methods under the new standard are the full retrospective method, in which the new standard would be applied to each prior reporting period presented and the cumulative effect of applying the new standard would be recognized at the earliest period shown, or the modified retrospective method, in which the cumulative effect of applying the new standard would be recognized at the date of initial application. In the fourth quarter of 2017, we substantially completed our assessment of the new standard, including completing our historical contract reviews and our evaluation of incremental costs of obtaining a contract. We will adopt the new standard on January 1, 2018 under the modified retrospective method. We expect an immaterial transition adjustment and an immaterial impact to our net earnings on an ongoing basis.
Concentration of Credit Risk	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers. The Company’s main financial institution for banking operations held 82% and 57% of the Company’s cash and cash equivalents as of December 31, 2017 and December 31, 2016 , respectively. The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Warranty Reserve	Product warranty reserve activity for the years ended December 31, 2017 and 2016 is as follows (in thousands): 2017 2016 Beginning balance $ 1 $ — Provisions 331 18 Warranty expenses incurred (140 ) (17 ) Ending balance $ 192 $ 1

Fair Value of Financial Instr28

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurement	The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company and the valuation approach applied to each class of financial instruments at December 31, 2017 and 2016 (see Note 2, Summary of Significant Accounting Policies for further information): December 31, 2017 (in thousands) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash and cash equivalents: Money market funds $ 7,832 $ — $ — $ 7,832 Investments: Certificates of deposit — 13,441 — 13,441 US Treasury securities 14,716 — — 14,716 US Agency securities — 8,459 — 8,459 Commercial paper — 9,171 — 9,171 Asset-backed securities — 3,025 — 3,025 Corporate notes and bonds — 31,836 — 31,836 Total investments 14,716 65,932 — 80,648 Total assets measured at fair value $ 22,548 $ 65,932 $ — $ 88,480 December 31, 2016 (in thousands) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Cash and cash equivalents: Money market funds $ 10,970 $ — $ — $ 10,970 Investments: Certificates of deposit — 7,257 — 7,257 US Treasury securities 8,544 — — 8,544 US Agency securities — 4,501 — 4,501 Asset-backed securities — 5,557 — 5,557 Corporate notes and bonds — 32,660 — 32,660 Total investments 8,544 49,975 — 58,519 Total assets measured at fair value $ 19,514 $ 49,975 $ — $ 69,489

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2017
Investments, Debt and Equity Securities [Abstract]
Summary of Available-for-sale Investments	The following tables summarize the Company’s available-for-sale investments at December 31, 2017 and 2016 (in thousands): AVAILABLE-FOR-SALE INVESTMENTS December 31, 2017 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Certificates of deposit $ 13,441 $ — $ — $ 13,441 US Treasury securities 14,787 — (71 ) 14,716 US Agency securities 8,510 — (51 ) 8,459 Commercial paper 9,171 — — 9,171 Asset-backed securities 3,026 — (1 ) 3,025 Corporate notes and bonds 31,906 — (70 ) 31,836 Total $ 80,841 $ — $ (193 ) $ 80,648 AVAILABLE-FOR-SALE INVESTMENTS December 31, 2016 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Certificates of deposit $ 7,257 $ — $ — $ 7,257 US Treasury securities 8,553 1 (10 ) 8,544 US Agency securities 4,514 — (13 ) 4,501 Asset-backed securities 5,554 3 — 5,557 Corporate notes and bonds 32,717 3 (60 ) 32,660 Total $ 58,595 $ 7 $ (83 ) $ 58,519
Summary of Maturities of Available-for-sale Investments	The following table summarizes the maturities of the Company’s available-for-sale securities at December 31, 2017 , and 2016 (in thousands): AVAILABLE-FOR-SALE INVESTMENT MATURITIES (in thousands) At December 31, 2017 At December 31, 2016 Amortized Cost Fair Value Amortized Cost Fair Value Due in less than 1 year $ 55,801 $ 55,735 $ 45,391 $ 45,344 Due in 1-5 years 25,040 24,913 13,204 13,175 Total $ 80,841 $ 80,648 $ 58,595 $ 58,519

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Components of Inventories	2017 2016 Raw materials $ 4,220 $ — Work in process 377 — Finished goods 3,466 — Inventory, net $ 8,063 $ —

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment are recorded at cost and consisted of the following at December 31, (in thousands). PROPERTY AND EQUIPMENT (in thousands) 2017 2016 Computer equipment $ 2,756 $ 2,270 Technical equipment 3,348 2,427 Facilities 3,621 3,387 Instruments 1,400 — Capital projects in progress 349 1,010 Total property and equipment $ 11,474 $ 9,094 Accumulated depreciation - other (6,584 ) (4,836 ) Net property and equipment $ 4,890 $ 4,258

Deferred Revenue and Income (Ta

Deferred Revenue and Income (Tables)	12 Months Ended
	Dec. 31, 2017
Deferred Revenue Disclosure [Abstract]
Deferred Revenue and Income Summary	A summary of the balances as of December 31, follows (in thousands): 2017 2016 Products and services not yet delivered 71 35 Arizona Commerce Authority grant 1,000 — Total current deferred revenue and income $ 1,071 $ 35 Arizona Commerce Authority grant $ — $ 1,000 Total long-term deferred income $ — $ 1,000

Employee and Consultant Equit33

Employee and Consultant Equity-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Activity	The following table summarizes option activity under all plans during the years ending December 31, 2017 , and December 31, 2016 and shows the exercisable shares as of December 31, 2017 : Stock Option Activity Number of Shares Weighted Average Exercise Price per Share Options Outstanding January 1, 2016 6,167,170 $ 6.91 Granted 1,024,050 14.05 Forfeited (147,663 ) 18.43 Exercised (158,743 ) 7.47 Expired (27,690 ) 4.87 Options Outstanding December 31, 2016 6,857,124 7.72 Granted 1,208,542 23.84 Forfeited (79,962 ) 17.82 Exercised (656,846 ) 8.93 Expired (727 ) 24.45 Options Outstanding December 31, 2017 7,328,131 10.16 Exercisable December 31, 2017 5,163,899 6.38
Black-Scholes Assumptions for Option Granted	The table below summarizes the inputs used to calculate the estimated fair value of options awarded during the respective periods: Black-Scholes Assumptions for Options Granted Years ended December 31, 2017 2016 2015 Expected term (in years) 6.23 6.43 6.26 Volatility 77 % 86 % 91 % Expected dividends — — — Risk free interest rates 2.1 % 1.6 % 1.7 % Estimated forfeitures — % 8.5 % 5.6 % Weighted average fair value $ 16.24 $ 10.35 $ 16.69
Stock Option Supplemental Information	The following table shows summary information for outstanding options and options that are exercisable (vested) as of December 31, 2017 : Stock Option Supplemental Information Options Outstanding Options Exercisable Number of options 7,328,131 5,163,899 Weighted average remaining contractual term (in years) 6.16 5.19 Weighted average exercise price $ 10.16 $ 6.38 Weighted average fair value $ 7.48 $ 4.74 Aggregate intrinsic value (in millions) $ 117.7 $ 102.4
Restricted Stock Activity	The following table summarizes RSU and SG activity during the years ending December 31, 2017 , and December 31, 2016 : RSU and SG Activity Number of Shares Weighted Average Grant Date Fair Value per Share RSU's & SG Outstanding January 1, 2016 40,250 20.91 Granted — — Forfeited — — Vested/released — — RSU's & SG's outstanding December 31, 2016 40,250 20.91 Granted 1,911 22.40 Forfeited — — Vested/released (18,011 ) 21.07 RSU's & SG's outstanding December 31, 2017 24,150 20.91
Weighted Average Fair Value of RSU's and SG's Awarded	The table below summarizes the weighted average fair value of RSU's and SG's awarded for the years ending December 31, : RSU and SG Grants 2017 2016 2015 Weighted average fair value 22.40 — 20.91
Equity-Based Compensation Expense and Tax Benefit	The expense and tax benefits recognized on the Company’s consolidated statements of operations and comprehensive loss related to options for the years ending December 31, is summarized below (in thousands): Equity-Based Compensation Expenses and Tax Benefit (in thousands) 2017 2016 2015 Cost of Sales $ 99 $ — $ — Research and development $ 3,738 $ 1,585 $ 2,479 Sales, general and administrative 10,096 7,190 5,909 Total equity-based compensation expense 13,933 8,775 8,388 Recognized tax benefit $ — $ — $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Pretax Loss from Operations	The components of the pretax loss from operations for the years ended December 31, are as follows (in thousands): 2017 2016 2015 U.S. Domestic $ (46,849 ) $ (48,539 ) $ (44,415 ) Foreign (16,686 ) (17,568 ) (1,083 ) Pretax loss from operations $ (63,535 ) $ (66,107 ) $ (45,498 )
Schedule of Provision for Income Taxes	The components of the provision for income taxes for the years ended December 31, is presented in the following table: 2017 2016 2015 Current: Federal $ — $ — $ — State — — — Foreign 493 267 — Total current provision 493 267 — Deferred: Federal — — — State — — — Foreign — — — Total deferred provision — — — Total provision $ 493 $ 267 $ —
Deferred Income Tax Components	Significant components of the Company’s net deferred income taxes for the years ended December 31, are as follows (in thousands): 2017 2016 Deferred tax assets: Net operating loss carryforward $ 41,086 $ 42,013 Property & equipment 524 690 Inventory 58 1,735 Stock options 8,195 7,208 Intangible assets, definite-lived 42 220 General business credit 6,651 3,984 Deferred revenue 253 370 Other 45 121 Valuation allowance (56,854 ) (56,341 ) Deferred tax assets $ — $ —
Effective Tax Rate	The difference between the U.S. federal statutory income tax rate and the Company’s effective tax rate for years ending December 31, is as follows: 2017 2016 2015 U.S. federal statutory income tax rate (34.00 )% (34.00 )% (34.00 )% State taxes, net of federal tax benefit (2.62 ) (1.69 ) (2.93 ) Permanent and other differences (2.31 ) (0.17 ) 0.11 Change in tax rates (1.02 ) 0.67 — Tax rate differential 8.99 8.62 0.42 Tax cuts and jobs act 38.46 — — Unrecognized tax benefits 1.20 1.09 0.40 Nondeductible equity and other compensation (4.31 ) 1.17 2.86 Limitation on net operating losses due to §382 — — — Credit for increased research activities (4.42 ) (3.31 ) (2.67 ) Change in Valuation allowance 0.81 28.02 35.81 0.78 % 0.40 % — %
Uncertain Tax Positions	as follows (in thousands): 2017 2016 2015 Balance at beginning of year $ 1,101 $ 343 $ 161 Increases for prior positions 97 37 — Increases for current year positions 943 721 182 Other increases — — — Decreases due to settlements — — — Expiration of the statute of limitations for the assessment of taxes — — — Other decreases — — — Balance at end of year $ 2,141 $ 1,101 $ 343

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Operating Leases Obligations	Future minimum lease payments under these agreements are as follows (in thousands): 2018 $ 1,119 2019 200 2020 84 2021 47 Thereafter 4 Total $ 1,454

Industry and Geographic Infor36

Industry and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Long-lived Assets by Geographic Territory	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long lived assets as of Total revenue December31, for the years ended December 31, 2017 2016 2017 2016 2015 Domestic $ 3,779 $ 4,150 $ 3,016 $ 238 $ 147 Foreign 1,111 108 1,161 8 — $ 4,890 $ 4,258 $ 4,177 $ 246 $ 147
Total Net Revenue by Geographic Territory	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long lived assets as of Total revenue December31, for the years ended December 31, 2017 2016 2017 2016 2015 Domestic $ 3,779 $ 4,150 $ 3,016 $ 238 $ 147 Foreign 1,111 108 1,161 8 — $ 4,890 $ 4,258 $ 4,177 $ 246 $ 147

Supplemental Data (Unaudited) (

Supplemental Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	December 31, September 30, June 30, March 31, 2017 2017 2017 2017 Revenue $ 2,120 $ 828 $ 699 $ 530 Gross profit $ 1,470 $ 637 $ 564 $ 504 Loss from operations $ (16,136 ) $ (17,315 ) $ (16,423 ) $ (14,310 ) Net loss $ (16,296 ) $ (17,075 ) $ (16,457 ) $ (14,200 ) Basic and diluted net loss per share $ (0.29 ) $ (0.31 ) $ (0.31 ) $ (0.27 ) December 31, September 30, June 30, March 31, 2016 2016 2016 2016 Revenue $ 39 $ 24 $ 20 $ 163 Gross profit $ 39 $ 24 $ 20 $ 163 Loss from operations $ (16,024 ) $ (17,416 ) $ (17,889 ) $ (15,172 ) Net loss $ (16,135 ) $ (17,299 ) $ (17,866 ) $ (15,074 ) Basic and diluted net loss per share $ (0.31 ) $ (0.34 ) $ (0.35 ) $ (0.29 )

Organization and Nature of Bu38

Organization and Nature of Business; Basis of Presentation; Principles of Consolidation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Depreciation and amortization expense	$ 2,200	$ 2,300	$ 1,800
Research and development | Reclassification
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Depreciation and amortization expense	1,100	1,400	1,100
Sales, general and administrative | Reclassification
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Depreciation and amortization expense	$ 632	$ 983	$ 672

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Instrument warranty term	1 year
Kits and accessories warranty term	60 days
Bundled rental agreement, term (under)	5 years
Dividend yield (percent)	0.00%
Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	1 year
Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	7 years

Summary of Significant Accoun40

Summary of Significant Accounting Policies Warranty Reserve (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 1,000	$ 0
Provisions	331,000	18,000
Warranty expenses incurred	(140,000)	(17,000)
Ending balance	$ 192,000	$ 1,000

Concentration of Credit Risk (D

Concentration of Credit Risk (Details) - Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash and Cash Equivalents
Concentration Risk [Line Items]
Risk concentration	82.00%	57.00%
Accounts Receivable | One Customer
Concentration Risk [Line Items]
Risk concentration	24.00%	29.00%

Fair Value of Financial Instr42

Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Investment [Line Items]
Total investments	$ 88,480	$ 69,489
Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	22,548	19,514
Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	65,932	49,975
Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0	0
Money market funds
Investment [Line Items]
Total investments	7,832	10,970
Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	7,832	10,970
Money market funds | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	0	0
Money market funds | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0	0
Certificates of deposit
Investment [Line Items]
Total investments	13,441	7,257
Certificates of deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	0	0
Certificates of deposit | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	13,441	7,257
Certificates of deposit | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0	0
US Treasury securities
Investment [Line Items]
Total investments	14,716	8,544
US Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	14,716	8,544
US Treasury securities | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	0	0
US Treasury securities | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0	0
US Agency securities
Investment [Line Items]
Total investments	8,459	4,501
US Agency securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	0	0
US Agency securities | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	8,459	4,501
US Agency securities | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0	0
Commercial paper
Investment [Line Items]
Total investments	9,171
Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	0
Commercial paper | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	9,171
Commercial paper | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0
Asset-backed securities
Investment [Line Items]
Total investments	3,025	5,557
Asset-backed securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	0	0
Asset-backed securities | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	3,025	5,557
Asset-backed securities | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0	0
Corporate notes and bonds
Investment [Line Items]
Total investments	31,836	32,660
Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	0	0
Corporate notes and bonds | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	31,836	32,660
Corporate notes and bonds | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	0	0
Total investments
Investment [Line Items]
Total investments	80,648	58,519
Total investments | Quoted Prices in Active Markets for Identical Assets (Level 1)
Investment [Line Items]
Total investments	14,716	8,544
Total investments | Significant Other Observable Inputs (Level 2)
Investment [Line Items]
Total investments	65,932	49,975
Total investments | Significant Unobservable Inputs (Level 3)
Investment [Line Items]
Total investments	$ 0	$ 0

Investments - Schedule of Avail

Investments - Schedule of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Investment [Line Items]
Amortized Cost	$ 80,841	$ 58,595
Gross Unrealized Gains	0	7
Gross Unrealized Losses	(193)	(83)
Fair Value	80,648	58,519
Certificates of deposit
Investment [Line Items]
Amortized Cost	13,441	7,257
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	13,441	7,257
US Treasury securities
Investment [Line Items]
Amortized Cost	14,787	8,553
Gross Unrealized Gains	0	1
Gross Unrealized Losses	(71)	(10)
Fair Value	14,716	8,544
US Agency securities
Investment [Line Items]
Amortized Cost	8,510	4,514
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(51)	(13)
Fair Value	8,459	4,501
Commercial paper
Investment [Line Items]
Amortized Cost	9,171
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	9,171
Asset-backed securities
Investment [Line Items]
Amortized Cost	3,026	5,554
Gross Unrealized Gains	0	3
Gross Unrealized Losses	(1)	0
Fair Value	3,025	5,557
Corporate notes and bonds
Investment [Line Items]
Amortized Cost	31,906	32,717
Gross Unrealized Gains	0	3
Gross Unrealized Losses	(70)	(60)
Fair Value	$ 31,836	$ 32,660

Investments - Schedule of Ava44

Investments - Schedule of Available-For-Sale Investment Maturities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Amortized Cost
Due in less than 1 year	$ 55,801	$ 45,391
Due in 1-5 years	25,040	13,204
Total	80,841	58,595
Fair Value
Due in less than 1 year	55,735	45,344
Due in 1-5 years	24,913	13,175
Total	$ 80,648	$ 58,519

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Proceeds from sales of marketable securities	$ 11,522,000	$ 9,716,000	$ 141,000
Realized gain on marketable securities	$ 0	6,000	$ 0
Gross proceeds associated with realized gains		$ 7,200,000

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 4,220,000	$ 0
Work in process	377,000	0
Finished goods	3,466,000	0
Inventory, net	$ 8,063,000	$ 0

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 11,474	$ 9,094
Accumulated depreciation - other	(6,584)	(4,836)
Net property and equipment	4,890	4,258
Depreciation expense	2,200	2,300	$ 1,800
Computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,756	2,270
Technical equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	3,348	2,427
Facilities
Property, Plant and Equipment [Line Items]
Total property and equipment	3,621	3,387
Instruments
Property, Plant and Equipment [Line Items]
Total property and equipment	1,400	0
Capital projects in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 349	$ 1,010

License Agreements and Grants -

License Agreements and Grants - National Institute of Health Grant (Details) - National Institute of Health Grant - USD ($) $ in Thousands	1 Months Ended	12 Months Ended			35 Months Ended
	Feb. 28, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Length of project (years)	5 years
Total grant funding	$ 5,000	$ 240	$ 74	$ 483
Cumulative sub-award					$ 885

License Agreements and Grants49

License Agreements and Grants - Arizona Commerce Authority and R&D Refundable Tax Credit Program (Details)	1 Months Ended		12 Months Ended
	Jan. 31, 2018USD ($)	Aug. 31, 2012USD ($)jobmilestone	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Research and Development [Abstract]
Arizona Commerce Authority grant		$ 1,000,000	$ 1,000,000
Number of milestones | milestone		4
Qualified jobs created, milestone 1 | job		15
Qualified jobs created, milestone 2 | job		30
Qualified jobs created, milestone 3 | job		40
Qualified jobs created, milestone 4 | job		65
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred revenue recognized			0	$ 114,000
Offset to research and development project			$ 0	$ 1,200,000	$ 647,000
Subsequent Event
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred revenue recognized	$ 1,000,000
Minimum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Capital investment milestone		$ 4,500,000
Grant related minimum annual wages		$ 63,000
Percent of company paid premiums		65.00%

Deferred Revenue and Income (De

Deferred Revenue and Income (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Aug. 31, 2012
Deferred Revenue Disclosure [Abstract]
Products and services not yet delivered		$ 71,000	$ 35,000
Arizona Commerce Authority grant		1,000,000	0
Total current deferred revenue and income		1,071,000	35,000
Arizona Commerce Authority grant		0	1,000,000
Total long-term deferred income		0	1,000,000
Milestone payments received		1,000,000		$ 1,000,000
Deferred Revenue Arrangement [Line Items]
Deferred revenue recognized		$ 0	$ 114,000
Subsequent Event
Deferred Revenue Arrangement [Line Items]
Deferred revenue recognized	$ 1,000,000

Stock Purchase (Details)

Stock Purchase (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / shares$ / warrantshares	Dec. 31, 2012USD ($)$ / shares$ / warrantshares	Jun. 26, 2017shares
Securities Financing Transactions Disclosures [Abstract]
Price per share (dollars per share) | $ / shares				$ 1.03
Stock and warrants purchase price | $				$ 14,400
Shares of common stock (shares)				14,000,000
Warrants to purchase common stock (shares)				7,000,000
Price per warrant (dollars per share) | $ / warrant			1.03	1.03
Additional warrant to purchase common stock (shares)			7,000,000	7,000,000
Price per warrant (dollars per share) | $ / warrant				2
Value of warrants | $				$ 5,900
Value of common stock | $				$ 8,500
Exercised warrant per purchase agreement (shares)			7,000,000
Exercised warrants (percent)			92.00%
Price per warrant (dollars per share) | $ / shares	$ 2	$ 2	$ 2
Additional exercised warrant per purchase agreement (shares)			6,400,000
Unexercised warrants (shares)		415,871	571,160		45,564
Proceeds from warrants | $	$ 741	$ 311	$ 20,100
Additional exercised warrant per purchase agreement (shares)	370,307	155,289

Public Offerings (Details)

Public Offerings (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 14, 2017	May 15, 2017	May 09, 2017	Dec. 15, 2015	Dec. 09, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Public offering price (dollars per share)					$ 17	$ 26.20
Underwriting discount and commission fees (dollars per share)					$ 1.19
Gross proceeds from sale of common stock				$ 109,300
Stock issuance costs				5,900		$ 0	$ 814	$ 0
Proceeds from common stock issuance				$ 103,400
Common stock
Class of Stock [Line Items]
Issuance of common stock and warrants (shares)				6,400,000		3,085,000		6,426,000
Common stock | Affiliated entity
Class of Stock [Line Items]
Issuance of common stock and warrants (shares)					2,900,000
Public offering | Common stock
Class of Stock [Line Items]
Issuance of common stock and warrants (shares)					5,600,000
Underwriters
Class of Stock [Line Items]
Sale of stock (shares)	335,000
Underwriters | Common stock
Class of Stock [Line Items]
Issuance of common stock and warrants (shares)			413,000		838,000
Offering exempt from underwriter commission | Common stock | Affiliated entity
Class of Stock [Line Items]
Issuance of common stock and warrants (shares)					2,400,000
Shares to the public | Pro-forma
Class of Stock [Line Items]
Sale of stock (shares)		2,800,000
Public offering
Class of Stock [Line Items]
Gross proceeds from sale of common stock	$ 89,000
Public offering price (dollars per share)			$ 28.85
Underwriting discounts and commissions (dollars per share)			$ 1.731
underwriting discounts, commissions and other costs	5,800
Net proceeds	$ 83,200
Public offering | Pro-forma
Class of Stock [Line Items]
Sale of stock (shares)			3,200,000

Related Party Transaction (Deta

Related Party Transaction (Details) $ in Thousands	1 Months Ended
	Jun. 30, 2016USD ($)
Recovery of short-swing profit
Related Party Transaction [Line Items]
Recovery of related party short-swing profits	$ 866

Earnings Per Share (Details)

Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Antidilutive common stock instruments outstanding (shares)	7,352,281	7,313,245	6,778,580

Employee and Consultant Equit55

Employee and Consultant Equity-Based Compensation - Non-Qualified Stock Option Plan (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of options (shares)	656,846	158,743
Outstanding (shares)	7,328,131	6,857,124	6,167,170
Non-Qualified Stock Option Plan | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Exercise of options (shares)	280,000
Outstanding (shares)	0
Options available (shares)	0

Employee and Consultant Equit56

Employee and Consultant Equity-Based Compensation - 2004 Omnibus Stock Option Plan (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jul. 31, 2012	Dec. 31, 2015	Dec. 31, 2004
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise of options (shares)	656,846	158,743
Outstanding (shares)	7,328,131	6,857,124		6,167,170
2004 Omnibus Stock Option Plan | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized (shares)			5,500,000		500,000
Additional shares authorized (shares)			5,000,000
Exercise of options (shares)	658,994
Outstanding (shares)	3,281,006
Options available (shares)	0

Employee and Consultant Equit57

Employee and Consultant Equity-Based Compensation - 2012 Omnibus Equity Incentive Plan (Details) - shares	1 Months Ended		12 Months Ended
	May 30, 2017	May 31, 2014	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercised (shares)			656,846	158,743
Outstanding (shares)			7,328,131	6,857,124	6,167,170
RSU's and SG's
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Released (shares)			18,011	0
2012 Omnibus Equity Incentive Plan | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options available (shares)		7,677,500	2,966,998			1,677,500
Additional shares authorized (shares)	2,000,000	4,000,000
Expiration period			10 years
Options exercised (shares)			621,216
Outstanding (shares)			4,071,275
Restricted new grants (shares)				200,000
2012 Omnibus Equity Incentive Plan | Stock Option | Vesting terms (i), cliff vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
2012 Omnibus Equity Incentive Plan | Stock Option | Vesting terms (ii), monthly vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
2012 Omnibus Equity Incentive Plan | Stock Option | Vesting terms (iv), annual vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			5 years
2012 Omnibus Equity Incentive Plan | Stock Option | Vesting terms (iv), two years after grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			2 years
Vesting percentage			40.00%
2012 Omnibus Equity Incentive Plan | Stock Option | Vesting terms (iv), monthly over next three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Vesting percentage			60.00%

Employee and Consultant Equit58

Employee and Consultant Equity-Based Compensation - Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares
Outstanding, beginning balance (shares)	6,857,124	6,167,170
Granted (shares)	1,208,542	1,024,050
Forfeited (shares)	(79,962)	(147,663)
Exercised (shares)	(656,846)	(158,743)
Expired (shares)	(727)	(27,690)
Outstanding, ending balance (shares)	7,328,131	6,857,124	6,167,170
Exercisable, ending balance (shares)	5,163,899
Weighted Average Exercise Price per Share
Outstanding, beginning balance (dollars per share)	$ 7.72	$ 6.91
Granted (dollars per share)	23.84	14.05
Forfeited (dollars per share)	17.82	18.43
Exercised (dollars per share)	8.93	7.47
Expired (dollars per share)	24.45	4.87
Outstanding, ending balance (dollars per share)	10.16	$ 7.72	$ 6.91
Exercisable, ending balance (dollars per share)	$ 6.38
Cash received from the exercise of options	$ 5,900,000
Tax benefit from share-based compensation	0
Intrinsic value of options exercised	12,100,000	$ 2,200,000	$ 2,000,000
Fair value of shares vesting	$ 12,000,000	$ 6,600,000	$ 7,300,000

Employee and Consultant Equit59

Employee and Consultant Equity-Based Compensation - Black-Scholes Assumptions for Option Granted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected term (in years)	6 years 2 months 23 days	6 years 5 months 5 days	6 years 3 months 4 days
Volatility	77.00%	86.00%	91.00%
Expected dividends	$ 0	$ 0	$ 0
Risk free interest rates	2.10%	1.60%	1.70%
Estimated forfeitures	0.00%	8.50%	5.60%
Weighted average fair value (dollars per share)	$ 16.24	$ 10.35	$ 16.69

Employee and Consultant Equit60

Employee and Consultant Equity-Based Compensation - Stock Option Supplemental Information (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 09, 2015	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value (in millions)			$ 5.9
Share price (dollars per share)	$ 26.20	$ 17
Options Outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options (shares)	7,328,131
Weighted average remaining contractual term (in years)	6 years 1 month 28 days
Weighted average exercise price (dollars per share)	$ 10.16
Weighted average fair value (dollars per share)	$ 7.48
Aggregate intrinsic value (in millions)	$ 117.7
Options Exercisable
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options (shares)	5,163,899
Weighted average remaining contractual term (in years)	5 years 2 months 9 days
Weighted average exercise price (dollars per share)	$ 6.38
Weighted average fair value (dollars per share)	$ 4.74
Aggregate intrinsic value (in millions)	$ 102.4

Employee and Consultant Equit61

Employee and Consultant Equity-Based Compensation - RSU nad SG Activity (Details) - RSU's and SG's - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of Shares
Beginning balance (shares)	40,250	40,250
Granted (shares)	1,911	0
Forfeited (shares)	0	0
Vested/Released (shares)	(18,011)	0
Ending balance (shares)	24,150	40,250	40,250
Weighted Average Grant Date Fair Value per Share
Beginning balance (dollars per share)	$ 20.91	$ 20.91
Granted (dollars per share)	22.40	0	$ 20.91
Forfeited (dollars per share)	0	0
Vested/released (dollars per share)	21.07	0
Ending balance (dollars per share)	$ 20.91	$ 20.91	$ 20.91

Employee and Consultant Equit62

Employee and Consultant Equity-Based Compensation - Weighted Average Fair Value of RSU's and SG's Awarded (Details) - RSU's and SG's - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (dollars per share)	$ 22.40	$ 0	$ 20.91
Fair value of units released	$ 379,000	$ 0	$ 0

Employee and Consultant Equit63

Employee and Consultant Equity-Based Compensation - Equity-Based Compensation Expense and Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 01, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 13,933	$ 8,775	$ 8,388
Recognized tax benefit	0	0	0
Unrecognized equity-based compensation cost	15,900
Cumulative impact of accounting change for forfeitures		(655)
Additional deferred tax asset related to stock options	8,195	7,208
ASU 2016-09
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional deferred tax asset related to stock options				$ 1,500
RSU's
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized equity-based compensation cost	174
Accumulated Deficit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cumulative impact of accounting change for forfeitures		(655)
Accumulated Deficit | ASU 2016-09
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cumulative impact of accounting change for forfeitures				$ 655
Cost of Sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	99	0	0
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	3,738	1,585	2,479
Sales, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	10,096	$ 7,190	$ 5,909
Capitalized inventory
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	304
Property and equipment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 48

Income Taxes - Components of th

Income Taxes - Components of the Pretax Loss From Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. Domestic	$ (46,849)	$ (48,539)	$ (44,415)
Foreign	(16,686)	(17,568)	(1,083)
Net loss before income taxes	$ (63,535)	$ (66,107)	$ (45,498)

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal	$ 0	$ 0	$ 0
State	0	0	0
Foreign	493	267	0
Total current provision	493	267	0
Deferred:
Federal	0	0	0
State	0	0	0
Foreign	0	0	0
Total deferred provision	0	0	0
Total provision	$ 493	$ 267	$ 0

Income Taxes - Deferred Income

Income Taxes - Deferred Income Taxes Components (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforward	$ 41,086	$ 42,013
Property & equipment	524	690
Inventory	58	1,735
Stock options	8,195	7,208
Intangible assets, definite-lived	42	220
General business credit	6,651	3,984
Deferred revenue	253	370
Other	45	121
Valuation allowance	(56,854)	(56,341)
Deferred tax assets	$ 0	$ 0

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ 56,854	$ 56,341
Unrecognized tax benefits	2,141	$ 1,101	$ 343	$ 161
Uncertain tax positions that would impact the effective tax rate	65
Domestic Tax Authority | Internal Revenue Service (IRS)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, Sec. 382 limitation	173,400
Gross operating loss carryforwards	4,200
Operating loss carryforwards	169,200
State and Local Jurisdiction | Arizona Department of Revenue
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 142,800

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U.S. federal statutory income tax rate	(34.00%)	(34.00%)	(34.00%)
State taxes, net of federal tax benefit	(2.62%)	(1.69%)	(2.93%)
Permanent and other differences	(2.31%)	(0.17%)	0.11%
Change in tax rates	(1.02%)	0.67%	(0.00%)
Tax rate differential	8.99%	8.62%	0.42%
Tax cuts and jobs act	38.46%	0.00%	0.00%
Unrecognized tax benefits	1.20%	1.09%	0.40%
Nondeductible equity and other compensation	(4.31%)	1.17%	2.86%
Limitation on net operating losses due to §382	(0.00%)	(0.00%)	(0.00%)
Credit for increased research activities	(4.42%)	(3.31%)	(2.67%)
Change in Valuation allowance	0.81%	28.02%	35.81%
Effective tax rate	0.78%	0.40%	(0.00%)

Income Taxes - Uncertain Tax Po

Income Taxes - Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Uncertain Tax Positions
Balance at beginning of year	$ 1,101	$ 343	$ 161
Increases for prior positions	97	37	0
Increases for current year positions	943	721	182
Other increases	0	0	0
Decreases due to settlements	0	0	0
Expiration of the statute of limitations for the assessment of taxes	0	0	0
Other decreases	0	0	0
Balance at end of year	$ 2,141	$ 1,101	$ 343

Commitments - Narrative (Detail

Commitments - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 1,300	$ 1,100	$ 685
Clinical trial master agreement expense	$ 27	$ 2,100	$ 1,600

Commitments - Operating Lease O

Commitments - Operating Lease Obligations (Details) $ in Thousands	Dec. 31, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 1,119
2,019	200
2,020	84
2,021	47
Thereafter	4
Total	$ 1,454

Industry and Geographic Infor72

Industry and Geographic Information - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)segment	Dec. 31, 2016USD ($)	Dec. 31, 2015
Segment Reporting [Abstract]
Number of operating segments | segment	1
Concentration Risk [Line Items]
Balances due	$ 1,946	$ 34
Total revenue | One Customer
Concentration Risk [Line Items]
Risk concentration	18.00%
Total revenue | Geographic Concentration | Outside the U.S.
Concentration Risk [Line Items]
Risk concentration	28.00%	3.00%	0.00%
Balances due from Foreign Customers | Geographic Concentration | Outside the U.S.
Concentration Risk [Line Items]
Balances due	$ 1,000	$ 3

Industry and Geographic Infor73

Industry and Geographic Information - Long-lived Assets and Total Net Revenue by Geographic Territory (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	$ 4,890				$ 4,258				$ 4,890	$ 4,258
Geographic Areas, Revenues from External Customers [Abstract]
Revenue	2,120	$ 828	$ 699	$ 530	39	$ 24	$ 20	$ 163	4,177	246	$ 147
Geographic Concentration | Long-lived assets
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	4,890				4,258				4,890	4,258
Geographic Concentration | Total revenue
Geographic Areas, Revenues from External Customers [Abstract]
Revenue									4,177	246	147
Geographic Concentration | Domestic | Long-lived assets
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	3,779				4,150				3,779	4,150
Geographic Concentration | Domestic | Total revenue
Geographic Areas, Revenues from External Customers [Abstract]
Revenue									3,016	238	147
Geographic Concentration | Foreign | Long-lived assets
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	$ 1,111				$ 108				1,111	108
Geographic Concentration | Foreign | Total revenue
Geographic Areas, Revenues from External Customers [Abstract]
Revenue									$ 1,161	$ 8	$ 0

Supplemental Data (Unaudited)74

Supplemental Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Revenue	$ 2,120	$ 828	$ 699	$ 530	$ 39	$ 24	$ 20	$ 163	$ 4,177	$ 246	$ 147
Gross profit	1,470	637	564	504	39	24	20	163	3,175	246	147
Loss from operations	(16,136)	(17,315)	(16,423)	(14,310)	(16,024)	(17,416)	(17,889)	(15,172)	(64,184)	(66,501)	(45,549)
Net loss	$ (16,296)	$ (17,075)	$ (16,457)	$ (14,200)	$ (16,135)	$ (17,299)	$ (17,866)	$ (15,074)	$ (64,028)	$ (66,374)	$ (45,498)
Basic and diluted net loss per share (dollars per share)	$ (0.29)	$ (0.31)	$ (0.31)	$ (0.27)	$ (0.31)	$ (0.34)	$ (0.35)	$ (0.29)